atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
August 09 2021 - 6:00PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that it plans to host a
conference call on Monday, August 16, 2021 at 8:30 a.m. ET to
discuss its financial results for the quarter ended June 30, 2021
and provide a business update.
To access the live conference call, please dial 877-407-3982
from the United States, or +1 (201) 493-6780 internationally, using
the conference ID: 13721888. The live and archived webcast of this
call will be available in the “Events” section of the atai Life
Sciences website at ir.atai.life.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders. atai's business model combines
funding, technology, scientific and regulatory expertise with a
focus on psychedelic therapy and other drugs with differentiated
safety profiles and therapeutic potential. By pooling resources and
best practices, atai aims to responsibly accelerate the development
of new medicines across its companies, seeking to effectively treat
and ultimately heal mental health disorders. atai's mission is to
bridge the gap between what the mental healthcare system currently
provides and what patients need. atai is headquartered in Berlin,
with offices in New York and London. For more information, please
visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including without limitation
statements regarding atai’s participation in upcoming conferences
and presentations and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors discussed under the caption “Risk Factors” in atai's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities
and Exchange Commission (“SEC”) on June 21, 2021, as such factors
may be updated from time to time in atai's other filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. atai disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, whether as a result of
new information, future events or otherwise, other than to the
extent required by applicable law.
Investor Contact:Greg Weaveratai – Chief
Financial OfficerEmail: greg.weaver@atai.life
Media Contact:Anne DonohoeKCSA Strategic
CommunicationsPhone: +1 (212) 896-1265Email: atai@KCSA.com
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024